sur EURAZEO (EPA:RF)
EURAZEO Leads €29 Million Series B for Germitec
The Nov Santé Actions Non Cotées Fund, managed by Eurazeo, has announced its participation in a €29 million Series B fundraising for Germitec. This investment highlights Eurazeo's commitment to strengthening its presence in the healthcare sector. Germitec, a French MedTech company based in Bordeaux, specializes in High-Level Disinfection solutions for ultrasound probes. Their innovative, chemical-free technology aims to reduce cross-contamination risks in medical environments.
With demand surging in the global disinfection market, Germitec is positioned as a significant player. The company already has a presence in over 40 countries and is targeting the U.S. market, having recently obtained FDA De Novo certification for its Chronos product. CEO Vincent Gardès expressed confidence in capturing the U.S. market opportunities.
This investment marks Eurazeo's third Growth Equity venture with Nov Santé Actions Non Cotées, further expanding their healthcare expertise.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de EURAZEO